The approval from the Safety Review Committee to proceed with the Phase 2a clinical trial for DA-1241 is a significant positive development for NeuroBo Pharmaceuticals. This step is crucial for the continuation of research and development in a potential treatment for MASH, indicating progress in their pipeline. Such regulatory milestones are typically viewed positively by investors and can lead to increased investor confidence and potential upward movement in the stock price in the short term.